TB patients get higher drug dose in quest for faster cure
NCT ID NCT06057519
First seen Jan 31, 2026 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This study tests whether a higher dose (1800 mg) of the antibiotic rifampicin is safe and works better than the standard dose for adults with lung tuberculosis. About 164 participants will be monitored for liver problems and other side effects, as well as how well the treatment clears the infection. The goal is to see if the higher dose can improve cure rates without causing more harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASL Città di Torino
RECRUITINGTurin, Italy
-
Radboud University Medical Centre
RECRUITINGNijmegen, Netherlands
Contact
Conditions
Explore the condition pages connected to this study.